The DOI matches its Crossref record.
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
Abstract
PURPOSE: We studied a multimodality approach using extrapleural pneumonectomy, chemotherapy, and radiotherapy in patients with malignant pleural mesothelioma. PATIENTS AND METHODS: From 1980 to 1992, 52 selected patients, underwent treatment. Median age was 53 years (range, 33 to 69). Initial patient evaluation was performed by a multimodality team. Pathologic diagnosis was reviewed and confirmed before therapy. Patients with no medical contraindication and potentially resectable mesothelioma on computed tomography (CT) (magnetic resonance imaging [MRI] when it became available) received extrapleural pneumonectomy, cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy, and radiotherapy. RESULTS: Perioperative morbidity and mortality rates were 17% and 5.8%, respectively. The overall median survival duration is 16 months (range, 1 month to 8 years). The 32 patients with epithelial histologic variant had 1-, 2-, and 3-year survival rates of 77%, 50%, and 42%, respectively. Patients with mixed and sarcomatous cell disease had 1- and 2-year survival rates of 45% and 7.5%; no patient lived longer than 25 months (P < .01). At resection, positive regional mediastinal lymph nodes were found in 13. Positive lymph nodes were associated with poorer survival than were negative nodes (P < .01). Patients with epithelial variant and negative mediastinal lymph nodes had a survival rate of 45% at 5 years. CONCLUSION: Multimodality therapy including extrapleural pneumonectomy has acceptable morbidity and mortality for selected patients. Prolonged survival occurred in patients with epithelial histologic variant and negative mediastinal lymph nodes. These data provide a rationale for a revised staging system for malignant pleural mesothelioma; furthermore, they permit stratification of patients into groups likely to benefit from aggressive multimodality treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., DeCamp, M. M., Swanson, S. J., Bueno, R., Lukanich, J. M., et al. (1999) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70469-1 · Cited by 985
Self-citationA Proposed New International TNM Staging System for Malignant Pleural Mesothelioma
(1995) · Chest · doi:10.1378/chest.108.4.1122 · Cited by 606
Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P. E., & Giaccone, G. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.145 · Cited by 543
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Boutin, C., Rey, F., & Viallat, J.-R. (1995) · Chest · doi:10.1378/chest.108.3.754 · Cited by 464
Metadata
- Authors
- Sugarbaker, D. J., Strauss, G. M., Lynch, T. J., Richards, W., Mentzer, S. J., Lee, T. H., Corson, J. M., & Antman, K. H.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-06
- Volume
- 11
- Issue
- 6
- Pages
- 1172-1178
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1836606828
- Cited by
- 246
- References
- 0
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. https://app.cochat.ai/papers/10.1200/jco.1993.11.6.1172
- The paper
- Sugarbaker, D. J., Strauss, G. M., Lynch, T. J., Richards, W., Mentzer, S. J., Lee, T. H., Corson, J. M., & Antman, K. H. (1993). Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.6.1172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.